Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis

Patent metadata

Field	Value
Publication number	US-12186379-B2
Application number	US-202117447607-A
Country	US
Kind code	B2
Filing date	Sep 14, 2021
Priority date	Jun 28, 2013
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

First claim

What is claimed is:

1. A method of inducing immune tolerance to myelin oligodendrocyte glycoprotein (MOG) in a patient comprising administering to the patient an effective amount of a composition comprising an anti-DC-ASGPR antibody attached to an antigenic fragment of MOG; and wherein the antigenic fragment of MOG consists of SEQ ID NO:37.

2. The method of claim 1 , wherein the anti-DC-ASGPR antibody is further attached to a tolerogenic adjuvant.

3. The method of claim 2 , wherein the tolerogenic adjuvant is IL-10, dexamethasone, FK506 (tacrolimus), cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B subunit, IFN-beta, a glucocorticoid, vitamin D3, or a TLR agonist.

4. The method of claim 3 , wherein the tolerogenic adjuvant is IL-10.

5. The method of claim 3 , wherein the tolerogenic adjuvant is a TLR agonist.

6. The method of claim 1 , wherein the patient has multiple sclerosis, neuropathy, central pontine myelinolysis, tabes dorsalis, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, or leukodystrophy.

7. The method of claim 6 , wherein the patient has multiple sclerosis.

8. A method for treating a demyelinating disease in a subject comprising administering to the subject a pharmaceutically acceptable vaccine composition comprising at least a first anti-DC-ASGPR antibody attached to an antigenic fragment of myelin oligodendrocyte glycoprotein (MOG), and wherein the antigenic fragment of MOG consists of SEQ ID NO:37.

9. The method of claim 8 , the anti-DC-ASGPR antibody is further attached to a tolerogenic adjuvant.

10. The method of claim 9 , wherein the tolerogenic adjuvant is IL-10, dexamethasone, FK506 (tacrolimus), cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B subunit, IFN-beta, a glucocorticoid, vitamin D3, or a TLR agonist.

11. The method of claim 10 , wherein the tolerogenic adjuvant is IL-10.

12. The method of claim 10 , wherein the tolerogenic adjuvant is a TLR agonist.

13. The method of claim 8 , wherein the demyelinating disease is multiple sclerosis, neuropathy, central pontine myelinolysis, tabes dorsalis, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, or leukodystrophy.

14. The method of claim 13 , wherein the demyelinating disease is multiple sclerosis.

15. A composition comprising an anti-DC-ASGPR antibody attached to an antigenic fragment of myelin oligodendrocyte glycoprotein (MOG); wherein the antigenic fragment of MOG consists of SEQ ID NO: 37.

16. The composition of claim 15 , further comprising a tolerogenic adjuvant attached to the anti-DC-ASGPR antibody.

17. The composition of claim 16 , wherein the tolerogenic adjuvant is IL-10, dexamethasone, FK506 (tacrolimus), cholera toxin B subunit, Escherichia coli heat-labile enterotoxin B subunit, IFN-beta, a glucocorticoid, vitamin D3, or a TLR agonist.

18. The composition of claim 17 , wherein the tolerogenic adjuvant is IL-10.

19. The composition of claim 17 , wherein the tolerogenic adjuvant is a TLR agonist.

Assignees

• Baylor Res Institute

Inventors

• Oh Sangkon
• Zurawski Gerard

Classifications

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K14/46

  from vertebrates · CPC title

• A61K2039/577

  tolerising response · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P25/00 Primary

  Drugs for disorders of the nervous system · CPC title